What is the difference between Minocycline Hydrochloride Extended-Release and Tigecycline?

Minocycline Hydrochloride Extended-Release and Tigecycline are both Tetracycline Antibiotics, so they work through the same broad mechanism. They differ in dosing, half-life, side-effect frequency, and how individual patients tolerate them. See the head-to-head sections below for the specifics.

Can Minocycline Hydrochloride Extended-Release and Tigecycline be used for the same conditions?

Both medications are prescribed for overlapping indications including use EMROSI only as indicated. ( 1 ). Always verify with your prescriber and the current FDA label before switching.

Is Emrosi the same as Tigecycline?

No. Emrosi (Minocycline Hydrochloride Extended-Release) and Tigecycline (Tigecycline) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Can I switch from Minocycline Hydrochloride Extended-Release to Tigecycline?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

Minocycline Hydrochloride Extended-Release vs Tigecycline

Compare Minocycline Hydrochloride Extended-Release (Emrosi) and Tigecycline (Tigecycline), clinical data, side effects, and patient experiences.

Minocycline Hydrochloride Extended-Release

Emrosi · Tetracycline Antibiotic

How it works

12.1 Mechanism of Action The mechanism of action of EMROSI for the treatment of rosacea is unknown.

Approved for

use EMROSI only as indicated. ( 1 )

OralTablet

Tigecycline

Tigecycline · Tetracycline Antibiotic

How it works

12.1 Mechanism of Action Tigecycline is a tetracycline class antibacterial [see Microbiology ( 12.4 )] .

Approved for

including ventilator-associated pneumonia ( 1.4 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of tigecycline for injection and other antibacterial drugs

Enterococcus faecalis (vancomycin-susceptible isolates)

Staphylococcus aureus (methicillin-susceptible and -resistant isolates)

Streptococcus agalactiae

IntravenousTablet

Quick Comparison

Minocycline Hydrochloride Extended-ReleaseTigecycline

Drug Class

Tetracycline Antibiotic

Route

Oral

Intravenous

Half-Life

N/A

FDA Approved

N/A

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Minocycline Hydrochloride Extended-Release

Drug Not Working

>10%

Nausea

1-10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Headache

1-10%

Condition Worsened

1-10%

Diarrhea

0.1-1%

Tigecycline

Drug Not Working

>10%

Nausea

1-10%

Vomiting

1-10%

Diarrhea

0.1-1%

Condition Worsened

0.1-1%

FDA Warnings

Minocycline Hydrochloride Extended-Release

5 WARNINGS AND PRECAUTIONS Serious Skin/Hypersensitivity Reactions: Minocycline has been associated with anaphylaxis, serious skin reactions, erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome
1 Hypersensitivity Reaction and Serious Skin Reactions Cases of anaphylaxis, serious skin reactions (e
In some cases, death has been reported
Advise the patient of the potential risk to the fetus if EMROSI is used during the second or third trimester of pregnancy [see Use in Specific Populations (8

Tigecycline

5 WARNINGS AND PRECAUTIONS All-Cause Mortality: A meta-analysis of Phase 3 and 4 clinical trials demonstrated an increase in all-cause mortality in tigecycline-treated patients compared to controls with a risk difference of 0
Patients who develop abnormal liver function tests during tigecycline for injection therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy
4 ) Pancreatitis: including fatalities, has been reported with tigecycline for injection
In all 13 Phase 3 and 4 trials that included a comparator, death occurred in 4% (150/3,788) of patients receiving tigecycline for injection and 3% (110/3,646) of patients receiving comparator drugs

Clinical Trial Data

No head-to-head clinical studies found for Minocycline Hydrochloride Extended-Release vs Tigecycline.

Minocycline Hydrochloride Extended-Release vs Tigecycline: What You Should Know

Key Differences

Both Minocycline Hydrochloride Extended-Release and Tigecycline belong to the Tetracycline Antibiotic class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. Minocycline Hydrochloride Extended-Release is administered via Oral, whereas Tigecycline uses Intravenous. Route of administration can affect onset of action and patient adherence.

Safety Considerations

Minocycline Hydrochloride Extended-Release carries 4 FDA warnings. Tigecycline carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

Doxycycline Monohydrate vs Tigecycline→Omadacycline vs Tigecycline→Doxycycline Monohydrate vs Minocycline Hydrochloride Extended-Release→Tetracycline Hydrochloride vs Tigecycline→Doxycycline vs Tigecycline→Doxycycline Hyclate vs Tigecycline→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

Minocycline Hydrochloride Extended-Release: DailyMed label · FAERS adverse events · ClinicalTrials.gov
Tigecycline: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

Minocycline Hydrochloride Extended-Release vs Tigecycline

Compare Minocycline Hydrochloride Extended-Release (Emrosi) and Tigecycline (Tigecycline), clinical data, side effects, and patient experiences.

Minocycline Hydrochloride Extended-Release

Emrosi · Tetracycline Antibiotic

How it works

12.1 Mechanism of Action The mechanism of action of EMROSI for the treatment of rosacea is unknown.

Approved for

use EMROSI only as indicated. ( 1 )

OralTablet

Tigecycline

Tigecycline · Tetracycline Antibiotic

How it works

12.1 Mechanism of Action Tigecycline is a tetracycline class antibacterial [see Microbiology ( 12.4 )] .

Approved for

including ventilator-associated pneumonia ( 1.4 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of tigecycline for injection and other antibacterial drugs

Enterococcus faecalis (vancomycin-susceptible isolates)

Staphylococcus aureus (methicillin-susceptible and -resistant isolates)

Streptococcus agalactiae

IntravenousTablet

Quick Comparison

Minocycline Hydrochloride Extended-ReleaseTigecycline

Drug Class

Tetracycline Antibiotic

Route

Oral

Intravenous

Half-Life

N/A

FDA Approved

N/A

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Minocycline Hydrochloride Extended-Release

Drug Not Working

>10%

Nausea

1-10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Headache

1-10%

Condition Worsened

1-10%

Diarrhea

0.1-1%

Tigecycline

Drug Not Working

>10%

Nausea

1-10%

Vomiting

1-10%

Diarrhea

0.1-1%

Condition Worsened

0.1-1%

FDA Warnings

Minocycline Hydrochloride Extended-Release

5 WARNINGS AND PRECAUTIONS Serious Skin/Hypersensitivity Reactions: Minocycline has been associated with anaphylaxis, serious skin reactions, erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome
1 Hypersensitivity Reaction and Serious Skin Reactions Cases of anaphylaxis, serious skin reactions (e
In some cases, death has been reported
Advise the patient of the potential risk to the fetus if EMROSI is used during the second or third trimester of pregnancy [see Use in Specific Populations (8

Tigecycline

5 WARNINGS AND PRECAUTIONS All-Cause Mortality: A meta-analysis of Phase 3 and 4 clinical trials demonstrated an increase in all-cause mortality in tigecycline-treated patients compared to controls with a risk difference of 0
Patients who develop abnormal liver function tests during tigecycline for injection therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy
4 ) Pancreatitis: including fatalities, has been reported with tigecycline for injection
In all 13 Phase 3 and 4 trials that included a comparator, death occurred in 4% (150/3,788) of patients receiving tigecycline for injection and 3% (110/3,646) of patients receiving comparator drugs

Clinical Trial Data

No head-to-head clinical studies found for Minocycline Hydrochloride Extended-Release vs Tigecycline.

Minocycline Hydrochloride Extended-Release vs Tigecycline: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

Minocycline Hydrochloride Extended-Release: DailyMed label · FAERS adverse events · ClinicalTrials.gov
Tigecycline: DailyMed label · FAERS adverse events · ClinicalTrials.gov